David Langley

US Patent:

20140011700, Jan 9, 2014

Filed:

Mar 23, 2012

Appl. No.:

14/003003

Inventors:

Eric T. Baldwin - Upper Holland PA, US
Patricia Ann McDonnell - Lumberville PA, US
Suzanne Edavettal - San Diego CA, US
Hal Lewis - Pennington NJ, US
Bradley C. Pearce - East Hampton CT, US
David R. Langley - Meriden CT, US
Christopher W. Cianci - Madison CT, US
Linda Discotto - New Britain CT, US
Samuel Gerritz - Guilford CT, US
Shuhao Shi - Madison CT, US
Shirong Zhu - Cheshire CT, US

International Classification:

C07K 14/005
G01N 33/68

US Classification:

506 9, 436501, 530358

Abstract:

The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer. Taken together, our data suggest a complex binding mode in which the compounds bind NP specifically in stoichiometric fashion inducing the formation of an NP oligomer without obstructing the RNA binding pocket or interfering with the native NP homo-oligomerization.

US Patent:

D2573296, Oct 14, 1980

Filed:

Dec 28, 1978

Appl. No.:

5/974143

Inventors:

David T. Langley - Philadelphia PA

International Classification:

D1004

US Classification:

D10 54

US Patent:

40260860, May 31, 1977

Filed:

Jul 18, 1975

Appl. No.:

5/597267

Inventors:

David T. Langley - Philadelphia PA

International Classification:

E04C 110
A63H 3308
H01F 702

US Classification:

52582

Abstract:

A new building brick for use in the construction of buildings is disclosed. The brick is provided with projecting members and indentations on opposite surfaces. The projecting members and indentations provide resistance to lateral movement of the bricks. The bricks are held together in adjacent tiers by means of magnetic forces. The magnetic materials are located around the periphery of the projecting members and indentations or on the tops of the projecting members and the innermost portion of the indentation. In another embodiment, the bricks may be partially cured and held together by means of applying water to the surfaces to be joined and applying heat.

US Patent:

20170369530, Dec 28, 2017

Filed:

Aug 9, 2017

Appl. No.:

15/672526

Inventors:

- Princeton NJ, US
Claudio Mapelli - Langhorne PA, US
Martin Patrick Allen - Flemington NJ, US
Michael S. Bowsher - Prospect CT, US
Kenneth M. Boy - Durham CT, US
Eric P. Gillis - Cheshire CT, US
David R. Langley - Meriden CT, US
Eric Mull - Guilford CT, US
Maude A. Poirier - Pennington NJ, US
Nishith Sanghvi - Bridgewater NJ, US
Li-Qiang Sun - Glastonbury CT, US
Daniel J. Tenney - Yardley PA, US
Kap-Sun Yeung - Madison CT, US
Juliang Zhu - North Haven CT, US
Patrick C. Reid - Tokyo, JP
Paul Michael Scola - Glastonbury CT, US

International Classification:

C07K 7/56
A61K 38/10
A61K 45/06
G01N 33/574
C07K 7/08
A61K 39/39
A61K 38/00

Abstract:

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

US Patent:

20170260237, Sep 14, 2017

Filed:

Sep 11, 2014

Appl. No.:

15/510138

Inventors:

- Princeton NJ, US
Claudio Mapelli - Langhorne PA, US
Martin Patrick Allen - Flemington NJ, US
Michael S. Bowsher - Prospect CT, US
Eric P. Gillis - Cheshire CT, US
David R. Langley - Meriden CT, US
Eric Mull - Guilford CT, US
Maude A. Poirier - Pennington NJ, US
Nishith Sanghvi - Bridgewater NJ, US
Li-Qiang Sun - Glastonbury CT, US
Daniel J. Tenney - Yardley PA, US
Kap-Sun Yeung - Madison CT, US
Juliang Zhu - North Haven CT, US
Kevin W. Gillman - Madison CT, US
Qian Zhao - Wallingford CT, US
Katharine A. Grant-Young - Madison CT, US
Paul Michael Scola - Glastonbury CT, US
Lyndon A.M. Cornelius - Jackson NJ, US

Assignee:

BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

International Classification:

C07K 7/64
A61K 45/06
A61K 38/12

Abstract:

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

US Patent:

20160158349, Jun 9, 2016

Filed:

Jan 28, 2016

Appl. No.:

15/009575

Inventors:

- Princeton NJ, US
Claudio Mapelli - Langhorne PA, US
Martin Patrick Allen - Flemington NJ, US
Michael S. Bowsher - Prospect CT, US
Kenneth M. Boy - Durham CT, US
Eric P. Gillis - Cheshire CT, US
David R. Langley - Meriden CT, US
Eric Mull - Guilford CT, US
Maude A. Poirier - Pennington NJ, US
Nishith Sanghvi - Bridgewater NJ, US
Li-Qiang Sun - Glastonbury CT, US
Daniel J. Tenney - Madison CT, US
Kap-Sun Yeung - Madison CT, US
Juliang Zhu - North Haven CT, US
Patrick C. Reid - Tokyo, JP
Paul Michael Scola - Glastonbury CT, US

International Classification:

A61K 39/39
A61K 45/06

Abstract:

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

US Patent:

20140294898, Oct 2, 2014

Filed:

Mar 10, 2014

Appl. No.:

14/201977

Inventors:

- Princeton NJ, US
Claudio Mapelli - Langhorne PA, US
Martin Patrick Allen - Flemington NJ, US
Michael S. Bowsher - Prospect CT, US
Kenneth M. Boy - Durham CT, US
Eric P. Gillis - Cheshire CT, US
David R. Langley - Meriden CT, US
Eric Mull - Guilford CT, US
Maude A. Poirier - Pennington NJ, US
Nishith Sanghvi - Franklin Park NJ, US
Li-Qiang Sun - Glastonbury CT, US
Daniel J. Tenney - Madison CT, US
Kap-Sun Yeung - Madison CT, US
Juliang Zhu - North Haven CT, US
Patrick C. Reid - Tokyo, JP
Paul Michael Scola - Glastonbury CT, US

International Classification:

C07K 7/08
A61K 45/06
A61K 38/10
A61K 39/39

US Classification:

4242781, 530327, 530326

Abstract:

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.